Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.42 |
| ▸ | CTSK | P43235 | 4/20 | 0.39 |
| ▸ | CTSS | P25774 | 3/20 | 0.39 |
| ▸ | JAK2 | O60674 | 2/20 | 0.36 |
| ▸ | JAK1 | P23458 | 2/20 | 0.36 |
| ▸ | JAK3 | P52333 | 2/20 | 0.36 |
| ▸ | DPP4 | P27487 | 2/20 | 0.35 |
| ▸ | CTSD | P07339 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.34 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.34 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | LSS | P48449 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23696902 | 1.00 | HSD11B1 (0.42) | HSD11B1CTSKCTSSJAK2JAK1 | |
| SCHEMBL4797314 | 1.00 | HSD11B1 (0.42) | HSD11B1CTSKCTSSJAK2JAK1 | |
| SCHEMBL5761307 | 0.83 | HSD11B1 (0.36) | HSD11B1JAK2JAK1JAK3ASGR1 | |
| SCHEMBL5761309 | 0.83 | HSD11B1 (0.36) | HSD11B1JAK2JAK1JAK3ASGR1 | |
| SCHEMBL190837 | 0.82 | HSD11B1 (0.47) | HSD11B1JAK2JAK1JAK3ASGR1 | |
| SCHEMBL23696267 | 0.81 | NR1H2 (0.43) | HSD11B1CTSKCTSSJAK2JAK1 | |
| SCHEMBL4805517 | 0.81 | NR1H2 (0.43) | HSD11B1CTSKCTSSJAK2JAK1 | |
| SCHEMBL24448742 | 0.81 | HSD11B1 (0.40) | HSD11B1CTSKCTSSJAK2JAK1 | |
| SCHEMBL343692 | 0.81 | NR1H2 (0.43) | HSD11B1CTSKCTSSJAK2JAK1 | |
| SCHEMBL24449604 | 0.81 | HSD11B1 (0.40) | HSD11B1CTSKCTSSJAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11779578-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11779578-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11707457-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230144292-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20210228562-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-07-29 | — | — | US | disclosed |
| WO-2021127190-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| CN-103282025-B | Melt-extruded solid dispersions containing apoptosis-inducing agents | 艾伯维爱尔兰无限公司 | 2018-01-02 | — | — | CN | disclosed |
| EP-1311475-B1 | AMINOCYCLOHEXANE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-08-06 | — | — | EP | disclosed |
| US-7335687-B2 | 2,3-Oxidosqualene-lanosterol cyclase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-20050176766-A1 | 2,3-Oxidosqualene-lanosterol cyclase inhibitors | ACKERMANN JEAN (CH) | 2005-08-11 | — | — | US | disclosed |
| US-6858651-B2 | 2,3-oxidosqualene-lanosterol cyclase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2005-02-22 | — | — | US | disclosed |
| EP-1311475-A1 | NOVEL AMINOCYCLOHEXANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-21 | — | — | EP | disclosed |
| US-20020045777-A1 | 2,3-oxidosqualene-lanosterol cyclase inhibitors | F.HOFFMANN-LA ROCHE AG (CH) | 2002-04-18 | — | — | US | disclosed |
| WO-2002014267-A1 | NOVEL AMINOCYCLOHEXANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210228562-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | HSD11B1 2834/4885CTSK 529/4885CTSS 1155/4885 |
| US-20050176766-A1 | 2,3-Oxidosqualene-lanosterol cyclase inhibitors | CYP51A1, LSS, CYP46A1 | HSD11B1 14/4885CTSK 1903/4885CTSS 1462/4885 |
| US-11779578-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | HSD11B1 2834/4885CTSK 529/4885CTSS 1155/4885 |
| US-20020045777-A1 | 2,3-oxidosqualene-lanosterol cyclase inhibitors | CYP51A1, LSS, CYP46A1 | HSD11B1 14/4885CTSK 1903/4885CTSS 1462/4885 |
| US-11707457-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | HSD11B1 2834/4885CTSK 529/4885CTSS 1155/4885 |
| US-20230144292-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | HSD11B1 2834/4885CTSK 529/4885CTSS 1155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.